Abilify for Borderline Personality Disorder
Abilify (aripiprazole) is NOT FDA-approved for borderline personality disorder and should not be used as a primary treatment. 1 Psychotherapy, specifically Dialectical Behavioral Therapy (DBT), is the only evidence-based first-line treatment for BPD. 2, 3, 2
Primary Treatment Recommendation
DBT is the only treatment proven to reduce suicidality and self-harm in BPD patients in randomized controlled trials. 2 This therapy combines CBT elements, skills training, and mindfulness techniques to develop emotion regulation, interpersonal effectiveness, and distress tolerance. 3 The treatment typically involves individual and group sessions over 12-24 weeks for adolescents (DBT-A) or one year for adults. 2
Role of Aripiprazole (If Considered)
While aripiprazole has shown some benefit in research studies for BPD symptoms, the evidence is limited and contradictory:
Research Evidence:
- One double-blind RCT (2006) found 15 mg/day aripiprazole improved depression, anxiety, anger, and multiple SCL-90-R domains over 8 weeks in 52 BPD patients. 4
- An 18-month follow-up showed sustained improvements. 5
- Aripiprazole augmentation (10-15 mg/day) helped sertraline-resistant BPD patients, particularly with impulsivity and psychotic-like symptoms. 6
Critical Limitations:
- A 2021 systematic review and meta-analysis found pharmacotherapies (including second-generation antipsychotics) were NOT able to consistently reduce BPD severity. 7 The evidence does not support pharmacotherapy alone for reducing BPD severity.
- A 2024 meta-analysis showed atypical antipsychotics produced only "small improvements" in psychosocial functioning, with "debatable clinical meaningfulness." 8
- A 2023 systematic review noted "considerable risk of bias" in both aripiprazole trials for BPD. 9
Practical Clinical Algorithm
If psychotherapy alone is insufficient and medication is being considered:
Target specific comorbid conditions first (depression, anxiety disorders, substance use) rather than BPD itself. 10
For severe impulsivity, anger, or transient psychotic symptoms that persist despite DBT:
Avoid polypharmacy and unsafe medications (those with overdose risk like benzodiazepines). 10
Reassess need for medication every 3-6 months as DBT skills develop.
Critical Caveats
- Never use aripiprazole as monotherapy without concurrent evidence-based psychotherapy. 10, 7
- The FDA black box warning notes increased suicidal thoughts/behaviors with antidepressant-like drugs in young adults—close monitoring is mandatory. 1
- Medication should only be adjunctive to BPD-specific psychotherapy, not a replacement. 10
- Of 87 medications used in clinical practice for BPD, only 9 have been studied, highlighting the lack of robust evidence. 7
The evidence strongly favors DBT as first-line treatment, with aripiprazole reserved only as a carefully monitored adjunct for specific target symptoms when psychotherapy alone proves insufficient.